Literature DB >> 6607955

Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.

M Rosenstein, T J Eberlein, S A Rosenberg.   

Abstract

We have investigated the subpopulations of T cells necessary to mediate the cure of established tumors in two models of successful adoptive immunotherapy. In C57BL/6 mice bearing palpable and disseminated FBL-3 lymphoma, both Lyt-1+ and Lyt-2+ cells played a major role in mediating the regression and permanent cure of mice, whereas in BALB/c mice bearing the Meth A sarcoma the adoptive transfer of Lyt-1+2+ cells played a major role in mediating the regression of tumors and the curing of disease. Identical experiments performed in hybrid (BALB/c X C57BL/6) mice yielded similar results, further supporting our initial observation and indicating that in these two adoptive transfer model systems it is the tumor and not the variable expression of Lyt antigens by the host that determines which T cell subpopulation is required to cure mice of tumors.

Entities:  

Mesh:

Year:  1984        PMID: 6607955

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Authors:  H F Dullens; W Vuist; M Van der Maas; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.

Authors:  S A Kadhim; J L Chin
Journal:  Urol Res       Date:  1991

5.  Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV40-induced mKSA fibrosarcoma.

Authors:  S Kadhim; J Barrington-Leigh
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice.

Authors:  H Ozawa; T Iwaguchi; T Kataoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line.

Authors:  G J Pommier; F L Garrouste; D Bettetini; J M Culouscou; M M Remacle-Bonnet
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations.

Authors:  P A Steerenberg; E Geerse; W H De Jong; R Burger; R J Scheper; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction.

Authors:  E Kuramoto; O Yano; S Shimada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.